Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Citigroup

Gilead Sciences (NASDAQ:GILD) had its target price increased by investment analysts at Citigroup from $165.00 to $188.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup‘s price objective would suggest a potential upside of 10.15% from the stock’s current price.

A number of other analysts have also commented on GILD. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Cantor Fitzgerald increased their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday. BMO Capital Markets reaffirmed an “outperform” rating and issued a $184.00 target price on shares of Gilead Sciences in a research report on Friday. HSBC lifted their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Finally, Needham & Company LLC set a $175.00 price target on shares of Gilead Sciences in a research report on Friday. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $168.44.

Gilead Sciences Stock Up 3.1%

GILD traded up $5.07 during trading on Friday, reaching $170.68. 11,287,214 shares of the stock traded hands, compared to its average volume of 6,816,813. Gilead Sciences has a fifty-two week low of $114.02 and a fifty-two week high of $175.65. The stock’s 50-day simple moving average is $150.33 and its two-hundred day simple moving average is $139.55. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock has a market cap of $211.63 billion, a price-to-earnings ratio of -63.93 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the prior year, the business earned $2.47 earnings per share. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, equities research analysts expect that Gilead Sciences will post -0.48 EPS for the current year.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of Gilead Sciences stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00. Following the transaction, the chief executive officer owned 577,133 shares of the company’s stock, valued at $85,785,049.12. The trade was a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 111,000 shares of company stock worth $15,877,860 over the last ninety days. Company insiders own 0.30% of the company’s stock.

Institutional Trading of Gilead Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Gilead Sciences in the second quarter valued at $15,393,785,000. State Street Corp raised its position in shares of Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after purchasing an additional 1,357,967 shares during the period. Amundi lifted its stake in shares of Gilead Sciences by 10.7% during the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after buying an additional 1,018,976 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $1,316,606,000. Finally, Deutsche Bank AG acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $918,387,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported third-quarter adjusted EPS of $2.55, well above the $2.19 consensus estimate, while revenue reached $8.3 billion versus expectations of $7.81 billion. Revenue increased 6.8% year over year, and the company raised its 2026 product-sales outlook to $31.0 billion-$31.3 billion from $30.1 billion-$30.4 billion. Gilead Beats Q3 Earnings on HIV Strength and Trodelvy Sales Growth
• Positive Sentiment: The core business, excluding Veklury, grew 16%—Gilead’s strongest growth in more than a decade. Biktarvy and the broader HIV franchise remained the primary growth engine, while Trodelvy sales rose 41.7% to $506 million and Livdelzi also contributed. Gilead Q3 2026 Earnings Call Transcript
• Positive Sentiment: Analysts raised their targets following the results: Needham to $200, Wells Fargo to $190, Morgan Stanley to $183 and Truist to $181. These revisions indicate improved confidence in near-term earnings momentum. Analysts Increase Forecasts After Upbeat Q3 Results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to $3.28 annually and a yield of approximately 1.9%. The company also secured Canadian reimbursement for Livdelzi, potentially broadening access, but agreed to a $45 million Texas settlement related to alleged unlawful provider incentives.
• Negative Sentiment: Longer-term concerns remain. Medicare price negotiations are expected to reduce Biktarvy’s price by about 38% beginning in 2028, potentially cutting annual revenue by roughly $1.5 billion. Analysts also note that recent HIV growth benefited from inventory and favorable channel timing, while oncology and immunology remain less established and the 2026 EPS outlook was reduced. Gilead Q3 Earnings Call Highlights and Pricing Risks

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.